非甾体抗炎药作为中轴型脊柱关节炎潜在改善病情药物
本文综述中轴型脊柱关节炎中非甾体抗炎药(NSAIDs)及生物制剂对脊柱放射学进展的改善病情作用;观察性研究提示NSAIDs可能有潜在改善病情效应,但两项随机试验结论不同,目前尚无明确阻止韧带骨赘形成的治疗策略。
要点
- NSAIDs是中轴型脊柱关节炎的一线药物治疗。
- 观察性研究提示NSAIDs对强直性脊柱炎有潜在改善病情效应。
- 两项随机试验对NSAIDs改善病情作用结论不同。
核心结论
- 现有中轴型脊柱关节炎药物是否在症状控制之外影响脊柱放射学进展仍无定论。
研究设计与样本
- 本文为综述,回顾NSAIDs与生物制剂在中轴型脊柱关节炎中改善病情作用的临床研究。
- 综述还检查NSAIDs对骨形成影响的遗传、动物和临床证据。
主要发现
- 强直性脊柱炎观察性研究提示NSAIDs有潜在改善病情效应。
- 两项随机试验对NSAIDs改善病情作用得出不同结论。
临床怎么用
- NSAIDs仍为中轴型脊柱关节炎一线药物治疗。
- 生物制剂包括肿瘤坏死因子抑制剂和白细胞介素-17抑制剂可供选择。
局限性
- 尚无明确阻止韧带骨赘形成的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonsteroidal antiinflammatory drugs (NSAIDs) are the first-line pharmacotherapy for patients with axial spondyloarthritis (SpA). In recent years, treatment options have expanded with the availability of biologic agents, including tumor necrosis factor inhibitors and interleukin-17 inhibitors. However, a treatment strategy that clearly prevents syndesmophyte formation has not been established. Observational studies of patients with ankylosing spondylitis indicated potential disease-modifying effects of NSAIDs, but two randomized trials came to different conclusions. More broadly, whether any of the currently available medications for axial SpA have an effect on spine radiographic progression, beyond symptom control, remains inconclusive. In this article, we will review clinical studies of the disease modification effects of NSAIDs and biologics in axial SpA; examine genetic, animal, and clinical evidence of the effects of NSAIDs on bone formation; and discuss how future studies may investigate the question of disease modification in axial SpA.
引用
- Wang R, Bathon JM, Ward MM, et al. Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis. Arthritis Rheumatol. 2020. PMID: 31705611. doi:10.1002/art.41164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。